Related Experiment Videos
New agents in the therapy of hormone-refractory patients with prostate cancer
1Department of Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA 02115-6084.
Seminars in Oncology
|February 1, 1995
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death.
Prostate cancer and prostatic diseases·2016
Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer.
Prostate cancer and prostatic diseases·2016
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.
Annals of oncology : official journal of the European Society for Medical Oncology·2015
Bone metastasis in cancer: from microenvironmental remodeling to precision therapy.
Seminars in oncology·2026
Rhabdomyolysis resulting from the interaction of rosuvastatin and abiraterone: A case study.
Seminars in oncology·2026
NK3 subsets are linked to NK cell exhaustion and immunotherapy responsiveness in tumor.
Seminars in oncology·2026
Dual alexithymia: A relational framework for clinical communication in oncology.
Seminars in oncology·2026